213 results on '"Kinikar, Aarti"'
Search Results
2. Resurgence of respiratory syncytial virus infection during COVID-19 pandemic in Pune, India
- Author
-
Bhardwaj, Sumit, Choudhary, Manohar Lal, Chadha, Mandeep S, Kinikar, Aarti, Bavdekar, Ashish, Gujar, Nilesh, dcosta, Pradeep, Kulkarni, Rajesh, Bafna, Sanjay, Salvi, Sonali, Padbidri, Vikram, and Potdar, Varsha
- Published
- 2024
- Full Text
- View/download PDF
3. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
- Author
-
Chinula, Lameck, Ziemba, Lauren, Brummel, Sean, McCarthy, Katie, Coletti, Anne, Krotje, Chelsea, Johnston, Benjamin, Knowles, Kevin, Moyo, Sikhulile, Stranix-Chibanda, Lynda, Hoffman, Risa, Sax, Paul E, Stringer, Jeffrey, Chakhtoura, Nahida, Jean-Philippe, Patrick, Korutaro, Violet, Cassim, Haseena, Fairlie, Lee, Masheto, Gaerolwe, Boyce, Ceejay, Frenkel, Lisa M, Amico, K Rivet, Purdue, Lynette, Shapiro, Roger, Mmbaga, Blandina Theophil, Patel, Faeezah, van Wyk, Jean, Rooney, James F, Currier, Judith S, Lockman, Shahin, Best, Brookie M, Blanchette, Cheryl D, Browning, Renee, Jaliaah, Nagawa, Mirochnick, Mark, Murtaugh, William A, Patras, Emmanuel, Whalen, Frances, Momper, Jeremiah D, Ponatshego, Ponego L, Tirelo, Lesedi, Seme, Boitshepo J, Modise, Georginah O, Raesi, Mpho S, Budu, Marian E, Ramogodiri, Moakanyi, Oliveira, Ricardo H, Hofe, Cristina B, de Abreu, Thalita Fernandes, Pestanha, Lorena M, João, Esaú, Sidi, Leon C, Fuller, Trevon, Cruz, Maria LS, Pinto, Jorge, Ferreira, Flãvia, Correa, Mãrio, Romeiro, Juliana, Pilotto, Jose H, Fernandes, Luis EBC, Moreira, Luiz F, Gomes, Ivete M, Naik, Shilpa, Nevrekar, Neetal, Mave, Vidya, Kinikar, Aarti, Horne, Elizea, Soma-Kasiram, Hamisha, Violari, Avy, Mathiba, Sisinyana R, Nyati, Mandisa, Theron, Gerhard, de Jager, Jeanne, Rossouw, Magdel, Rossouw, Lindie, Hanley, Sherika, Desmond, Alicia C, Gazu, Rosemary, Govender, Vani, Chalermchockcharoenkit, Amphan, Thamkhantho, Manopchai, Werarak, Peerawong, Rungmaitree, Supattra, Achalapong, Jullapong, Sitiritkawin, Lukkana, Cressey, Tim R, Sukrakanchana, Pra-ornsuda, Aurpibul, Linda, Tongprasert, Fuanglada, Khamrong, Chintana, Kiattivej, Sopida, Wabwire, Deo, Kabugo, Enid, Maena, Joel, Nakayiwa, Frances, Ndyanabangi, Victoria, Nagaddya, Beatrice, Sekabira, Rogers, Ashaba, Justus, and Mitchell, Charles D
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Mental Health ,Infectious Diseases ,Pediatric ,HIV/AIDS ,Clinical Research ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Reproductive health and childbirth ,Infection ,Good Health and Well Being ,Pregnancy ,Child ,Female ,Humans ,Male ,HIV Infections ,Anti-HIV Agents ,Tenofovir ,Benzoxazines ,Emtricitabine ,Adenine ,RNA ,Viral Load ,IMPAACT 2010/VESTED Study Team and Investigators ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundDrugs taken during pregnancy can affect maternal and child health outcomes, but few studies have compared the safety and virological efficacy of different antiretroviral therapy (ART) regimens. We report the primary safety outcomes from enrolment up to 50 weeks post partum and a secondary virological efficacy outcome at 50 weeks post partum of three commonly used ART regimens for HIV-1.MethodsIn this multicentre, open-label, randomised, controlled, phase 3 trial, we enrolled pregnant women aged 18 years or older with confirmed HIV-1 infection at 14-28 weeks of gestation. Women were enrolled at 22 clinical research sites in nine countries (Botswana, Brazil, India, South Africa, Tanzania, Thailand, Uganda, the USA, and Zimbabwe). Participants were randomly assigned (1:1:1) to one of three oral regimens: dolutegravir, emtricitabine, and tenofovir alafenamide; dolutegravir, emtricitabine, and tenofovir disoproxil fumarate; or efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Up to 14 days of antepartum ART before enrolment was permitted. Women with known multiple gestation, fetal anomalies, acute significant illness, transaminases more than 2·5 times the upper limit of normal, or estimated creatinine clearance of less than 60 mL/min were excluded. Primary safety analyses were pairwise comparisons between ART regimens of the proportion of maternal and infant adverse events of grade 3 or higher up to 50 weeks post partum. Secondary efficacy analyses at 50 weeks post partum included a comparison of the proportion of women with plasma HIV-1 RNA of less than 200 copies per mL in the combined dolutegravir-containing groups versus the efavirenz-containing group. Analyses were done in the intention-to-treat population, which included all randomly assigned participants with available data. This trial was registered with ClinicalTrials.gov, NCT03048422.FindingsBetween Jan 19, 2018, and Feb 8, 2019, we randomly assigned 643 pregnant women to the dolutegravir, emtricitabine, and tenofovir alafenamide group (n=217), the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group (n=215), and the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (n=211). At enrolment, median gestational age was 21·9 weeks (IQR 18·3-25·3), median CD4 count was 466 cells per μL (308-624), and median HIV-1 RNA was 903 copies per mL (152-5183). 607 (94%) women and 566 (92%) of 617 liveborn infants completed the study. Up to the week 50 post-partum visit, the estimated probability of experiencing an adverse event of grade 3 or higher was 25% in the dolutegravir, emtricitabine, and tenofovir alafenamide group; 31% in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group; and 28% in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (no significant difference between groups). Among infants, the estimated probability of experiencing at least one adverse event of grade 3 or higher by postnatal week 50 was 28% overall, with small and non-statistically significant differences between groups. By postnatal week 50, 14 infants whose mothers were in the efavirenz-containing group (7%) died, compared with six in the combined dolutegravir groups (1%). 573 (89%) women had HIV-1 RNA data available at 50 weeks post partum: 366 (96%) in the dolutegravir-containing groups and 186 (96%) in the efavirenz-containing group had HIV-1 RNA less than 200 copies per mL, with no significant difference between groups.InterpretationSafety and efficacy data during pregnancy and up to 50 weeks post partum support the current recommendation of dolutegravir-based ART (particularly in combination with emtricitabine and tenofovir alafenamide) rather than efavirenz, emtricitabine, and tenofovir disoproxil fumarate, when started in pregnancy.FundingNational Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health.
- Published
- 2023
4. Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial
- Author
-
Paradkar, Mandar S, D, Bella Devaleenal, Mvalo, Tisungane, Arenivas, Ana, Thakur, Kiran T, Wolf, Lisa, Nimkar, Smita, Inamdar, Sadaf, Giridharan, Prathiksha, Selladurai, Elilarasi, Kinikar, Aarti, Valvi, Chhaya, Khwaja, Saltanat, Gadama, Daphne, Balaji, Sarath, Kattagoni, Krishna Yadav, Venkatesan, Mythily, Savic, Radojka, Swaminathan, Soumya, Gupta, Amita, Gupte, Nikhil, Mave, Vidya, Dooley, Kelly E, Agiwal, Shivali, Ahire, Rupali, Balasubramanian, Usha, Bendre, Manjushree, Chandane, Jyoti, Chopade, Kavita, Dalimbkar, Shamala, Deshpande, Prasad, Dhage, Rajendra, Ithape, Mahesh, Jadhav, Varsha, Kante, Sonali, Kapre, Pallavi, Khan, Nawshaba, Kulkarni, Vandana, Madewar, Renu, Meshram, Shashibhushan, Muttha, Kunal, Nadgeri, Vaishali, Nagargoje, Arti, Nagraj, Amita, Nijampurkar, Aparna, Onawale, Prerana, Pawar, Namrata, Pawar, Prashant, Pradhan, Neeta, Shaikh, Varsha, Shaikh, Zaheda, Shere, Dhananjay, Wani, Gouri, Kulkarni, Rajesh, Rajput, Uday, Ganesan, Mangalambal, Arasan, Gunasundari, Shankar, Shakila, Mary, S Stella, Karuppaiah, Sureshwari, Pauline, Leema, Pramila, Snegha Karunakaran, Arul, Priyadharshini, Ganesh, Sankar, Hanna, Luke Elizabeth, Ramesh, K, Kannan, M, Vijayakumar, Ruthra, Sivakumar, Surekha S, Devika, K, Radhakrishnan, A, Preethi, AR, Rajkumar, S, Saravanan, N, Ramachandran, Geetha, Kumar, AK Hemanth, Dharman, M, Sudha, V, Hissar, Syed, Nagarajan, Valarmathi, Jennifer, Linda, Supriya, R, Manimegalai, R, Kandan, Santhanam, Maniselvi, Archana, Puspha, Oli, Vaishnavi, S, Selvi, R, Neelakandan, Logeswari, Chiunda, Mary, Chunga, Moreen, Kamanga, Madalo, Kamthunzi, Portia, Kanthiti, Elizabeth, Mbewe, Abineli, Msiska, Emmie, Mumba, Noel, Phiri, Ian Zifa, Palichina, Victor, and Sichali, Dorothy
- Subjects
Pediatric ,Clinical Trials and Supportive Activities ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adult ,Child ,Humans ,Rifampin ,Tuberculosis ,Meningeal ,Levofloxacin ,Ethambutol ,Antitubercular Agents ,Standard of Care ,pediatric tuberculous meningitis ,neuropsychological ,clinical trial ,levofloxacin ,high-dose rifampicin ,TuBerculous Meningitis in Kids (TBM-KIDS) Study Team ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundPediatric tuberculous meningitis (TBM) commonly causes death or disability. In adults, high-dose rifampicin may reduce mortality. The role of fluoroquinolones remains unclear. There have been no antimicrobial treatment trials for pediatric TBM.MethodsTBM-KIDS was a phase 2 open-label randomized trial among children with TBM in India and Malawi. Participants received isoniazid and pyrazinamide plus: (i) high-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, arm 1); (ii) high-dose rifampicin and levofloxacin (R30HZL, arm 2); or (iii) standard-dose rifampicin and ethambutol (R15HZE, arm 3) for 8 weeks, followed by 10 months of standard treatment. Functional and neurocognitive outcomes were measured longitudinally using Modified Rankin Scale (MRS) and Mullen Scales of Early Learning (MSEL).ResultsOf 2487 children prescreened, 79 were screened and 37 enrolled. Median age was 72 months; 49%, 43%, and 8% had stage I, II, and III disease, respectively. Grade 3 or higher adverse events occurred in 58%, 55%, and 36% of children in arms 1, 2, and 3, with 1 death (arm 1) and 6 early treatment discontinuations (4 in arm 1, 1 each in arms 2 and 3). By week 8, all children recovered to MRS score of 0 or 1. Average MSEL scores were significantly better in arm 1 than arm 3 in fine motor, receptive language, and expressive language domains (P
- Published
- 2022
5. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis
- Author
-
Hamada, Yohhei, Gupta, Rishi K., Quartagno, Matteo, Izzard, Abbie, Acuna-Villaorduna, Carlos, Altet, Neus, Diel, Roland, Dominguez, Jose, Floyd, Sian, Gupta, Amita, Huerga, Helena, Jones-López, Edward C., Kinikar, Aarti, Lange, Christoph, van Leth, Frank, Liu, Qiao, Lu, Wei, Lu, Peng, Rueda, Irene Latorre, Martinez, Leonardo, Mbandi, Stanley Kimbung, Muñoz, Laura, Padilla, Elisabeth Sánchez, Paradkar, Mandar, Scriba, Thomas, Sester, Martina, Shanaube, Kwame, Sharma, Surendra K., Sloot, Rosa, Sotgiu, Giovanni, Thiruvengadam, Kannan, Vashishtha, Richa, Abubakar, Ibrahim, and Rangaka, Molebogeng X.
- Published
- 2023
- Full Text
- View/download PDF
6. Development of shortened HIV-related stigma scales for young people living with HIV and young people affected by HIV in India
- Author
-
Marbaniang, Ivan, Borse, Rohidas, Sangle, Shashikala, Kinikar, Aarti, Chavan, Amol, Nimkar, Smita, Suryavanshi, Nishi, and Mave, Vidya
- Published
- 2022
- Full Text
- View/download PDF
7. Breastfeeding in Coronavirus Disease 2019 (COVID-19): Position Statement of Indian Academy of Pediatrics and Infant and Young Child Feeding Chapter
- Author
-
Bharadva, Ketan, Bellad, Roopa M., Tiwari, Satish, Somasekar, R., Phadke, Mrudula, Bodhankar, Uday, Bang, Akash, Kinikar, Aarti Avinash, Mallikarjuna, H. B., Shah, Jayant, Khurana, Omesh, Gunasingh, D., Basavaraja, G. V., Kumar, Remesh, and Gupta, Piyush
- Published
- 2022
- Full Text
- View/download PDF
8. Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis
- Author
-
Mave, Vidya, Kinikar, Aarti, Kagal, Anju, Nimkar, Smita, Koli, Hari, Khwaja, Sultanat, Bharadwaj, Renu, Gerona, Roy, Wen, Anita, Ramachandran, Geetha, Kumar, Hemanth, Bacchetti, Peter, Dooley, Kelly E, Gupte, Nikhil, Gupta, Amita, and Gandhi, Monica
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Tuberculosis ,Orphan Drug ,Rare Diseases ,Patient Safety ,Infectious Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Antitubercular Agents ,Area Under Curve ,Child ,Preschool ,Humans ,Isoniazid ,Prospective Studies ,General Science & Technology - Abstract
We measured hair and plasma concentrations of isoniazid among sixteen children with tuberculosis who underwent personal or video-assisted directly observed therapy and thus had 100% adherence. This study therefore defined typical isoniazid exposure parameters after two months of treatment among fully-adherent patients in both hair and plasma (plasma area under the concentration-time curve, AUC, estimated using pharmacokinetic data collected 0, 2, 4, and 6 hours after drug administration). We found that INH levels in hair among highly-adherent individuals did not correlate well with plasma AUC or trough concentrations, suggesting that each measure may provide incremental and complementary information regarding drug exposure in the context of TB treatment.
- Published
- 2017
9. Service delivery challenges in HIV care during the first year of the COVID‐19 pandemic: results from a site assessment survey across the global IeDEA consortium
- Author
-
Brazier, Ellen, Ajeh, Rogers, Maruri, Fernanda, Musick, Beverly, Freeman, Aimee, Wester, C. William, Lee, Man?Po, Shamu, Tinei, Ramírez, Brenda Crabtree, D' Almeida, Marcelline, Wools?Kaloustian, Kara, Kumarasamy, N., Althoff, Keri N., Twizere, Christella, Grinsztejn, Beatriz, Tanser, Frank, Messou, Eugène, Byakwaga, Helen, Duda, Stephany N., Nash, Denis, Chansilpa, Chidchon, Dougherty, Trevor, Karminia, Azar, Law, Matthew, Ross, Jeremy, Sohn, Annette, Aguirre, Ivette, Baker, David, Bloch, Mark, Cabot, Safaa, Carr, Andrew, Couldwell, Deborah, Edwards, Sian, Eu, Beng, Farlow, Heather, Finlayson, Robert, Gunathilake, Manoji, Hazlewood, Cherie, Hoy, Jennifer, Langton?Lockton, Julian, Le, Jacqueline, Leprince, Elizabeth, Minc, Ariane, Moore, Richard, O'Sullivan, Maree, Roth, Norm, Rowling, Dianne, Russell, Darren, Ryder, Nathan, Saunders, Craig, Silvers, Julie, Smith, David J., Sowden, David, Sweeney, Grant, Tan, Lynn, Teague, Ricard, Templeton, David, Thng, Caroline, Woolley, Ian, Khol, Vohith, Ly, Penh Sun, Li, Tsz Hei, Po, Lee Man, Kinikar, Aarti, Kumarasamy, Nagalingeswaran, Mundhe, Sanjay, Pujari, Sanjay, Sangle, Shashikala, Nimkar, Smita, Jassin, Madelein, Kurniati, Nia, Merati, Tuti Parwati, Muktiarti, Dina, Amalia, Rizqi, Sukmawati, Ni Made Dewi Dian, Wati, Ketut Dewi Kumara, Yunihastuti, Evy, Tanuma, Junko, Choi, Jun Yong, Azwa, Raja Iskandar Shah Raja, Cheng, Chan Kwai, Gani, Yasmin Mohamed, Mohamed, Thahira Jamal, Moy, Fong Siew, Nallusamy, Revathy, Nor, Mohamad Zulfahami Mohd, Rudi, Nuraini, Shyan, Wong Peng, Yusoff, Nik Khairulddin Nik, Ditangco, Rossana, Chan, Yu?Jiun, Wu, Pei?Chieh, Wu, Ping?Feng, Avihingsanon, Anchalee, Chaiwarith, Romanee, Chokephaibulkit, Kulkanya, Khusuwan, Suwimon, Kiertiburanakul, Sasisopin, Kosalaraksa, Pope, Lumbiganon, Pagakrong, Ounchanam, Pradtana, Puthanakit, Thanyawee, Rungmaitree, Supattra, Solai, Nuttarika, Sudjaritruk, Tavitiya, An, Vu Thien, Cuong, Do Duy, Do, Chau Viet, Huy, Bui Vu, Quy, Tuan, Van Nguyen, Kinh, Nguyen, Luan, Nguyen, Van Lam, Nguyen, Yen Thi, Nong, Vuong Minh, Truong, Huu Khanh, Tuyen, Ngo Thi Thu, Mcgowan, Catherine C., Duda, Stephany, Cahn, Florencia, Cahn, Pedro, Cesar, Carina, Fink, Valeria, Sued, Omar, Coelho, Lara, Machado, Daisy Maria, Pinto, Jorge, Wolff, Marcelo, Rouzier, Vanessa, Padgett, Denis, Gotuzzo, Eduardo, Biziragusenyuka, Jérémie, Gateretse, Patrick, Nimbona, Pelagie, Niyonkuru, Olive, Twizere, Christelle, Anicetus, Surreng, Djenabou, Amadou, Enow, Priscilla, Mbu, Eyongetah, Manga, Martin, Ndobe, Mercy, Nasah, Judith, Ekossono, Elle Nathalie Syntyche, Bouseko, Mireille Teno, Kitetele, Faustin, Lelo, Patricia, Diafouka, Merlin Isidore Justin, Mafoua, Adolphe, Nsonde, Dominique Mahambou, Bihira, Uitonze Aime Maurice, Dusabe, Marie Chantal, Feza, Rosine, Habanabashaka, Jean Claude, Habumuremyi, Viateur, Igizeneza, Ernestine, Kamigisha, Anne Marie, Kubwimana, Gallican, Maniriho, Gilbert, Mbaraga, Gilbert, Muhoza, Benjamin, Mukakarangwa, Jeanne, Mukamana, Joyce, Mukanyirigira, Patricie, Mukeshimana, Yvone Claude, Munyaneza, Athanase, Murenzi, Gad, Musaninyange, Jacqueline, Nyiraneza, Jules Ndumuhire, Ntarambirwa, Fidele, Nyiraneza, Marie Louise, Tuyishime, Josette, Tuyishimire, Yvonne, Ubandutira, Alexis, Umugiraneza, Florance, Umugwaneza, Rosine, Uwamahoro, Olive, Uwamahoro, Pauline, Uwambaje, Marie Victoire, Uwimpuhwe, Clarisse, Uwiragiye, Siphora, Kuhn, Yee Yee, Adera, Felix, Adhiambo, Beatricec, Aggrey, Khaemba, Akadikor, Daniel, Ambulla, Felix, Apiyo, Dorah, Ariya, Patrick, Atemba, Naftal, Ayodi, Fridah, Benard, Chirchir, Bett, Maureen, Birgen, Serafine, Bwalei, Rael, Chebon, Nancy, Chebor, Valentine Jirry, Chebuiywo, Philip, Chemutai, Jacline, Chepkorir, Emily, Chepseba, Carolyne, Chirchir, John, Diero, Lameck, Dukwa, Benard, Elphas, Alice, Etyang, Tom, Idiama, Agnes, Jebichuko, Ann, Jepchumba, Delvine, Juma, Churchill, Juma, Maureen, Juma, Sheila, Kadima, Julie, Karani, Rose, Keitany, Christopher, Keter, Pricilla, Kiavoga, Lucy, Kibet, Harrison, Kimutai, Ruth, Kiplagat, Mutai, Kiprono, Wilfred, Kipruto, Nicholas Kogei, Kirimi, Asenath, Koech, Zeddy, Kosgei, Carolyne, Kutto, Karen, Kweyu, Mildred, Liech, Ephraim Kenneth, Limo, Milka, Maina, Rose, Marumbu, Priscah, Masese, Agnes, Mochotto, Patricia, Molly, Omudeck, Momanyi, Tom, Murutu, John W., Mwanda, Praxidis, Ndakalu, Lillian, Nderitu, Rose N., Obatsa, Sarah, Obiga, Fredrick, Oboya, Moses, Odhiambo, Joseph, Olaya, George, Omanyala, Oscar, Oray, Christine, Otieno, Molly, Otwane, Modesta Toto, Ouma, Paul, Owuor, Charles, Pepela, Doris Tutu, Pessah, Collins, Rotich, Evans, Rotich, Edwin K., Rutto, Titus C., Shikuku, Monica, Sibweche, Rose Naliaka, Simiyu, Robert Wanyonyi, Siria, Hellen, Some, Michael, Songok, Winnie Cherotich, Tanui, Immaculate, Wafula, Grace, Wambura, Rebecca, Wanjala, Ellah, Wanyama, Carolyne, Wanyonyi, Hellen, Woyakapel, Emmanuel, Zelbabel, Wandera, Gwimo, Dikengela, Kinyota, Ester, Lwali, Jerome, Lyamuya, Rita, Machemba, Richard, Mathias, Julia, Mkombachepa, Lilian, Mokiwa, Athuman, Mushi, Ombeni, Ndunguru, Charles, Ngonyani, Kapella, Nyaga, Charles, Ruta, Happiness, Urassa, Mark, Akanyihayo, James, Arinaitwe, Arnold, Batuuka, Jesca, Birungi, Walusimbi, Bugembe, John Nyanzi, Ddungu, Ahmed, Francis, Kato, Imran, Bangira, Kafuuma, George William, Kalulue, John Bosco, Kanaabi, Grace, Kanyesigye, Michale, Karuhanga, Godfery, Kasozi, Charles, Kasule, Godfrey, Katusime, Assumpta, Kibalama, Donozio, Kimera, Simon Peter, Kulusumu, Namatovu, Lule, Yusuf, Lwanga, Isaac, Mluindwa, Margaret, Moses, Jemba, Mubarak, Sseremba, Muggaga, Daniel, Mukalazi, Evelyn, Muleebwa, Joseph, Mulema, Derick, Musisi, Ivan, Muwawu, John, Muyindike, Winnie, Mwaka, Dick, Naava, Milly, Nabiyki, Immaculate, Nabusulwa, Agnes, Nakabugo, Dorah, Nakamya, Esther, Nakanwagi, Daisy, Nakato, Oliver, Nakayi, Lydian, Nakigozi, Patience, Nakku, Juliet, Nakuya, Juliet, Nakyomu, Justine, Namayanja, Joan, Namirembe, Sarah, Namugumya, Juliet, Namukasa, Ezereth, Namulindwa, Viola, Nankya, Irene, Nannyondo, Grace Mugagga, Nansamba, Harriet, Nansera, Denis, Nanyanzi, Brenda, Nanyonjo, Esther Celina, Nayiga, Irene, Opira, Isaac, Owarwo, Noela C., Resty, Sserunkuma, Semuwemba, Haruna, Senoga, Julius, Sseguya, Gerald, Ssekyewa, John Paul, Ssemakadde, Matthew, Tebajjwa, Jonah, Tugumisirize, Doreen, Tushemerirwe, Robinah, Waliyi, Kawuki, Althoff, Keri, Bishop, Jennifer, Gill, M J., Loutfy, Mona, Smith, Graham, Bamford, Laura, Black, Anthony, Brice, Asia, Brown, Sheldon, Colasanti, Jonathan, Duarte, Piper, Firnhaber, Cynthia, Goetz, Matthew, Grasso, Chris, Gripshover, Barbara, Horberg, Michael, Kelly, Rita, Levine, Ken, Luu, Mitchell, Marconi, Vincent, Maroney, Karen, Mayer, Kenneth, Mayor, Angel, Mcgowan, Catherine, Multani, Ami, Napravnik, Sonia, Nijhawan, Ank, Novak, Richard, Palella, Frank, Rodriguez, Maria C., Scott, Mia, Tedaldi, Ellen, Willig, James, Cornell, Morna, Davies, Mary?Ann, Egger, Matthias, Haas, Andreas, Bereng, Monkoe, Kalake, Maleshoane, Lenela, Keketso, Seretse, Relebohile, Chintenga, Matthews, Chiwoko, Jane, Gumulira, Joe, Huwa, Jacqueline, Maluwa, Rafique, Matanje, Beatrice, Mbewe, Ronald, Mfungwe, Sunshine, Mphande, Zakaliah, Tweya, Hannock, Rafael, Idiovino, Apolles, Patti, Beneke, Eunice, Dlamini, Siphephelo, Edson, Claire, Eley, Brian, Euvrard, Jonathan, Fatti, Geoffrey, Goeieman, Bridgette, Grimwood, Ashraf, Huang, David, Hugo, Susan, Ismail, Zahiera, Jennings, Lauren, Mathenjwa, Thulile, Monteith, Lizette, Mshweshwe, Zamuxolo, Ntuli, Mfundi, Ndlovu, En, Ndlozi, Hloniphile, Noyakaza, Sylvia, Prozesky, Hans, Rabie, Helena, Sipambo, Nosisa, Technau, Karl?Günter, Tembe, Thokozani, Xaba, Nontando, Njobvu, Thandiwe, Munthaly, Mary, Mwetwa, Elly, Kabeba, Gillian, Mwendafilumba, Derrick, Maanguka, Ethel, Manyika, Nelly, Mwansa, Chalwe, Banda, Future, Mwenda, Dickson, Bwalya, Abel, Shapi, Leah, Syame, Kasapo, Sashi, Rita, Mulenga, Chisha, Nanyangwe, Ruth, Chimbetete, Cleophas, Chinofunga, A., Mhike, J., Mubvigwi, E., Nyika, F., Quarter, Kumbirai Pise, Arikawa, Shino Chassagne, Becquet, Renaud, Bernard, Charlotte, Dabis, François, Desmonde, Sophie, Dahourou, Désiré, Ekouevi, Didier Koumavi, Jaquet, Antoine, Jesson, Julie, Leroy, Valeriane, Malateste, Karen, Rabourdin, Elodie, Tiendrebeogo, Thierry, Assogba, Michée, Zannou, Djimon Marcel, Hounhoui, Ghislaine, Bere, Denise, Poda, Armel, Pooda, Gbolo, Traore, Richard, Abauble, Yao, Abby, Ouattara, Acquah, Patrick, Andoble, Valérie, Aude, Yobo N'Dzama, Azani, Jean?Claude, Berete, Oka, Beugre, Jacques Daple, Bohoussou, Caroline Yao, Brou, Simon Boni Emmanuel, Chenal, Henri, Cissé, Abdoulaye, Coulibaly, Nambate, Dainguy, Marie Evelyne, Daligou, Marcelle, D' Aquin, Toni Thomas, Dasse, Claude Desire, Folquet, Madeleine Amorissani, Gnepa, Guy, Gobe, Olivier, Guira, Salif, Hawerlander, Denise, Horo, Apollinaire, Kanga, Guillaume, Messou, Zobo Konan Eugène, Minga, Kla Albert, Moh, Raoul, N'Gbeche, Mariesylvie, Ogbo, Patricia, Oulai, Mathieu, Stéphanie, Se, Eboua, Tanoh, Valère, Itchy Max, Afrane, Adwoa Kumiwa Asare, Akrofi, Esther, Andoh, John Christian, Renner, Lorna, Bagayoko, Awa, Bagayoko, Kadidiatou, Bah, Abdou Salam, Berthe, Alima, Coulibaly, Boureïma, Coulibaly, Fatimata, Coulibaly, Yacouba Aba, Diakité, Aïssata, Bocoum, Fatoumata, Boré, Fatoumata, Dicko, Fatoumata, Koné, Odile, Sylla, Mariam, Tangara, Assitan, Traoré, Mamadou, Seydi, Moussa, Amegatse, Edmond, Djossou, Julienne, Takassi, Elom, and Palanga, Sénam
- Subjects
HIV (Viruses) -- Care and treatment -- Patient outcomes ,Public health administration -- Evaluation ,Health - Abstract
: Introduction: Interruptions in treatment pose risks for people with HIV (PWH) and threaten progress in ending the HIV epidemic; however, the COVID‐19 pandemic's impact on HIV service delivery across diverse settings is not broadly documented. Methods: From September 2020 to March 2021, the International epidemiology Databases to Evaluate AIDS (IeDEA) research consortium surveyed 238 HIV care sites across seven geographic regions to document constraints in HIV service delivery during the first year of the pandemic and strategies for ensuring care continuity for PWH. Descriptive statistics were stratified by national HIV prevalence ( Results: Questions about pandemic‐related consequences for HIV care were completed by 225 (95%) sites in 42 countries with low (n = 82), medium (n = 86) and high (n = 57) HIV prevalence, including low‐ (n = 57), lower‐middle (n = 79), upper‐middle (n = 39) and high‐ (n = 50) income countries. Most sites reported being subject to pandemic‐related restrictions on travel, service provision or other operations (75%), and experiencing negative impacts (76%) on clinic operations, including decreased hours/days, reduced provider availability, clinic reconfiguration for COVID‐19 services, record‐keeping interruptions and suspension of partner support. Almost all sites in low‐prevalence and high‐income countries reported increased use of telemedicine (85% and 100%, respectively), compared with less than half of sites in high‐prevalence and lower‐income settings. Few sites in high‐prevalence settings (2%) reported suspending antiretroviral therapy (ART) clinic services, and many reported adopting mitigation strategies to support adherence, including multi‐month dispensing of ART (95%) and designating community ART pick‐up points (44%). While few sites (5%) reported stockouts of first‐line ART regimens, 10–11% reported stockouts of second‐ and third‐line regimens, respectively, primarily in high‐prevalence and lower‐income settings. Interruptions in HIV viral load (VL) testing included suspension of testing (22%), longer turnaround times (41%) and supply/reagent stockouts (22%), but did not differ across settings. Conclusions: While many sites in high HIV prevalence settings and lower‐income countries reported introducing or expanding measures to support treatment adherence and continuity of care, the COVID‐19 pandemic resulted in disruptions to VL testing and ART supply chains that may negatively affect the quality of HIV care in these settings., INTRODUCTION The COVID‐19 pandemic has had major direct and indirect impacts on population health globally, through disruptions in the accessibility and quality of basic health services [1], in supply chains [...]
- Published
- 2022
- Full Text
- View/download PDF
10. Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines.
- Author
-
Wilkinson, Thomas, Garcia-Prats, Anthony J., Sachs, Tina, Paradkar, Mandar, Suryavanshi, Nishi, Kinikar, Aarti, Frias, Melchor V., Sinanovic, Edina, Hesseling, Anneke C., Seddon, James. A., and Palmer, Megan
- Subjects
RIFAMPIN ,DRUG prices ,ECONOMIC research ,TUBERCULOSIS ,COST analysis ,TEENAGERS - Abstract
Rifampicin-resistant (RR) tuberculosis (TB) in children is a major global health concern but is often neglected in economics research. Accurate cost estimations across the spectrum of paediatric RR-TB treatment regimens are critical inputs for prioritisation and budgeting decisions, and an existing knowledge gap at local and international levels. This normative cost analysis was nested in a Phase I/II pharmacokinetics, safety, tolerability, and acceptability trial of TB medications in children in South Africa, the Philippines and India. It assessed the pharmaceutical costs of 36 childhood RR-TB regimens using combinations from 16 different medicines in 34 oral formulations (adult and child-friendly) in 11 weight bands in children <15 years of age. The analysis used local and Global Drug Facility pricing, and local and international guideline recommendations, including adaptions of BPaL and BPaLM regimens in adults. Costs varied significantly between regimen length, age/weight banding, severity of disease, presence of fluroquinolone resistance, and different country guideline recommendations. WHO recommended regimen costs ranged 12-fold: from US$232 per course (short regimen in non-severe disease) to US$2,761 (long regimen in severe, fluroquinolone-resistant disease). Regimen treating fluoroquinolone-resistant infection cost US$1,090 more than comparable WHO-recommended regimen. Providing child-friendly medicine formulations in <5-year-olds across all WHO-recommended regimens is expected to cost an additional $380 (range $212-$563) per child but is expected to have wider benefits including palatability, acceptability, adherence, tolerability, and dose accuracy. There were substantial differences in regimen affordability between countries when adjusted for purchasing power and domestic spending on health. Appropriate, effective, and affordable treatment options are an important component of the fight against childhood RR-TB. A comprehensive understanding of the cost and affordability dynamics of treatment options will enable national TB programs and global collaborations to make the best use of limited healthcare resources for the care of children with RR-TB. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Knowledge, attitude, and practices among police force toward covid-19 pandemic during Lockdown in Pune, India - An Online cross-sectional survey
- Author
-
D Sonkawade Naresh, A Kinikar Aarti, Rajesh Kulkarni, Chhaya Valvi, Uday C Rajput, Rahul Dawre, Sameer Pawar, Tushar Jadhav, Ajay Chandanwale, Muralidhar Tambe, K Venkatesham, and Nishi Suryavanshi
- Subjects
covid-19 ,knowledge ,lockdown ,police ,practices ,Medicine - Abstract
Background: COVID-19 has affected millions of people and more than thirty thousand deaths. Social distancing and lockdown are important measures for prevention. Police personnel are losing their lives due to COVID-19 while doing their duty in this lockdown time. Aim: The study aims to assess knowledge, attitude, and practices (KAP) of police force toward COVID-19. To assess correlation of knowledge with their practices and attitude. Materials and Methods: A cross-sectional, self-administered, anonymous survey questionnaire was administered to 8706 police personnel and data collected over a time period from April 11 to 16, 2020. We used t-test and multivariable binary logistic regression analysis to identify the association between KAP and demographic variables. Results: In all 8706 police personnel participated in the study. The median age of participants was 35 years (interquartile range: 19–59), 6787 (77.9%) were male, 6675 (76.6%) were of constable grade. Seven thousand three hundred thirty-two (83.7%) of participants recorded accurate (high) knowledge, and 6790 (78%) reported following preventive practices. Female participants were more likely to follow preventive measures despite low knowledge as compared to their male counterparts (P < 0.0001). Female gender, age more than 35 years, and lower rank were associated with low knowledge and fear of contracting the disease. Multivariable binary logistic regression analysis showed that low knowledge is significantly associated with fear of getting disease odds ratio 1.29; 95% confidence interval (1.15–1.46). Conclusion: In a cohort of police personnel, overall knowledge about COVID-19 is high. Female participants are found to be practicing appropriate preventive measures and they have faced stigmatizing behavior from society. The study provides important information on the need for developing health awareness programs to improve COVID-19 KAP.
- Published
- 2021
- Full Text
- View/download PDF
12. Improving the longevity of intravenous cannulas in sick neonates admitted to NICU in a tertiary care centre: a quality improvement project
- Author
-
Vadapalli, Sailusha, primary, Valvi, Chhaya, additional, Nagpal, Rema S, additional, Dawre, Rahul M, additional, and Kinikar, Aarti A, additional
- Published
- 2023
- Full Text
- View/download PDF
13. Intensified Short Symptom Screening Program for Dengue Infection during Pregnancy, India
- Author
-
Naik, Shilpa, Robinson, Matthew L., Alexander, Mallika, Chandanwale, Ajay, Sambarey, Pradip, Kinikar, Aarti, Bharadwaj, Renu, Sapkal, Gajanan N., Chebrolu, Puja, Deshpande, Prasad, Kulkarni, Vandana, Nimkar, Smita, Mave, Vidya, Gupta, Amita, and Mathad, Jyoti
- Subjects
Conjunctivitis -- Diagnosis ,Dengue fever -- Diagnosis ,Pregnancy ,Pregnant women ,Time ,Polymerase chain reaction ,Malaria ,Intelligence gathering ,Rash ,Women ,Diseases ,Health - Abstract
Every year, an estimated 96 million persons worldwide are given a clinical diagnosis of severe dengue infection (1). In 2017, a total of 188,401 cases of dengue were diagnosed in [...]
- Published
- 2020
- Full Text
- View/download PDF
14. Analytical Study of a Case Series Of Vancomycin Associated Adverse Drug Reactions In Paediatric Population at a Tertiary Care Hospital: A Brief Report
- Author
-
Fernandes, Madeline, primary, Daswani, Bharti, additional, Aringale, Vrushali, additional, and Kinikar, Aarti, additional
- Published
- 2023
- Full Text
- View/download PDF
15. Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children
- Author
-
Dutta, Noton K., Tornheim, Jeffrey A., Fukutani, Kiyoshi F., Paradkar, Mandar, Tiburcio, Rafael T., Kinikar, Aarti, Valvi, Chhaya, Kulkarni, Vandana, Pradhan, Neeta, Shivakumar, Shri Vijay Bala Yogendra, Kagal, Anju, Gupte, Akshay, Gupte, Nikhil, Mave, Vidya, Gupta, Amita, Andrade, Bruno B., and Karakousis, Petros C.
- Published
- 2020
- Full Text
- View/download PDF
16. Maternal Syphilis : An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission
- Author
-
Kinikar, Aarti, Gupte, Nikhil, Bhat, Jayalakshmi, Bharadwaj, Renu, Kulkarni, Vandana, Bhosale, Ramesh, McIntire, Katherine N, Mave, Vidya, Suryavanshi, Nishi, Patil, Sandesh, Bollinger, Robert, and Gupta, Amita
- Published
- 2017
17. Sources of household air pollution and their association with fine particulate matter in low-income urban homes in India
- Author
-
Elf, Jessica L., Kinikar, Aarti, Khadse, Sandhya, Mave, Vidya, Suryavanshi, Nishi, Gupte, Nikhil, Kulkarni, Vaishali, Patekar, Sunita, Raichur, Priyanka, Breysse, Patrick N., Gupta, Amita, and Golub, Jonathan E.
- Published
- 2018
- Full Text
- View/download PDF
18. Integration of HIV care into maternal and child health services in the global IeDEA consortium
- Author
-
Humphrey, John, primary, Nagel, Elizabeth, additional, Carlucci, James G., additional, Edmonds, Andrew, additional, Kinikar, Aarti, additional, Anderson, Kim, additional, Leroy, Valériane, additional, Machado, Daisy, additional, Yin, Dwight E., additional, Tulio Luque, Marco, additional, Amorissani-Folquet, Madeleine, additional, Mbewe, Safari, additional, Suwanlerk, Tulathip, additional, Munyaneza, Athanase, additional, Patel, Rena C., additional, Musick, Beverly, additional, Abuogi, Lisa, additional, and Wools-Kaloustian, Kara, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents : a systematic review and individual patient data meta-analysis
- Author
-
Gafar, Fajri, Wasmann, Roeland E., McIlleron, Helen M., Aarnoutse, Rob E., Schaaf, H. Simon, Marais, Ben J., Agarwal, Dipti, Antwi, Sampson, Bang, Nguyen D., Bekker, Adrie, Bell, David J., Chabala, Chishala, Choo, Louise, Davies, Geraint R., Day, Jeremy N., Dayal, Rajeshwar, Denti, Paolo, Donald, Peter R., Engidawork, Ephrem, Garcia-Prats, Anthony J., Gibb, Diana, Graham, Stephen M., Hesseling, Anneke C., Heysell, Scott K., Idris, Misgana I., Kabra, Sushil K., Kinikar, Aarti, Kumar, Agibothu K. Hemanth, Kwara, Awewura, Lodha, Rakesh, Magis-Escurra, Cecile, Martinez, Nilza, Mathew, Binu S., Mave, Vidya, Mduma, Estomih, Mlotha-Mitole, Rachel, Mpagama, Stellah G., Mukherjee, Aparna, Nataprawira, Heda M., Peloquin, Charles A., Pouplin, Thomas, Ramachandran, Geetha, Ranjalkar, Jaya, Roy, Vandana, Ruslami, Rovina, Shah, Ira, Singh, Yatish, Sturkenboom, Marieke G. G., Svensson, Elin M., Swaminathan, Soumya, Thatte, Urmila, Thee, Stephanie, Thomas, Tania A., Tikiso, Tjokosela, Touw, Daan J., Turkova, Anna, Velpandian, Thirumurthy, Verhagen, Lilly M., Winckler, Jana L., Yang, Hongmei, Yunivita, Vycke, Taxis, Katja, Stevens, Jasper, Alffenaar, Jan-Willem C., Gafar, Fajri, Wasmann, Roeland E., McIlleron, Helen M., Aarnoutse, Rob E., Schaaf, H. Simon, Marais, Ben J., Agarwal, Dipti, Antwi, Sampson, Bang, Nguyen D., Bekker, Adrie, Bell, David J., Chabala, Chishala, Choo, Louise, Davies, Geraint R., Day, Jeremy N., Dayal, Rajeshwar, Denti, Paolo, Donald, Peter R., Engidawork, Ephrem, Garcia-Prats, Anthony J., Gibb, Diana, Graham, Stephen M., Hesseling, Anneke C., Heysell, Scott K., Idris, Misgana I., Kabra, Sushil K., Kinikar, Aarti, Kumar, Agibothu K. Hemanth, Kwara, Awewura, Lodha, Rakesh, Magis-Escurra, Cecile, Martinez, Nilza, Mathew, Binu S., Mave, Vidya, Mduma, Estomih, Mlotha-Mitole, Rachel, Mpagama, Stellah G., Mukherjee, Aparna, Nataprawira, Heda M., Peloquin, Charles A., Pouplin, Thomas, Ramachandran, Geetha, Ranjalkar, Jaya, Roy, Vandana, Ruslami, Rovina, Shah, Ira, Singh, Yatish, Sturkenboom, Marieke G. G., Svensson, Elin M., Swaminathan, Soumya, Thatte, Urmila, Thee, Stephanie, Thomas, Tania A., Tikiso, Tjokosela, Touw, Daan J., Turkova, Anna, Velpandian, Thirumurthy, Verhagen, Lilly M., Winckler, Jana L., Yang, Hongmei, Yunivita, Vycke, Taxis, Katja, Stevens, Jasper, and Alffenaar, Jan-Willem C.
- Abstract
Background Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level. Methods We systematically searched MEDLINE, Embase and Web of Science (1990–2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration–time curve from 0 to 24 h post-dose (AUC0–24) and peak plasma concentration (Cmax) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC0–24 and Cmax were assessed with linear mixed-effects models. Results Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC0–24 were summarised for isoniazid (18.7 (95% CI 15.5–22.6) h·mg·L−1), rifampicin (34.4 (95% CI 29.4–40.3) h·mg·L−1), pyrazinamide (375.0 (95% CI 339.9–413.7) h·mg·L−1) and ethambutol (8.0 (95% CI 6.4–10.0) h·mg·L−1). Our multivariate models indicated that younger age (especially <2 years) and HIV-positive status were associated with lower AUC0–24 for all first-line anti-TB drugs, while severe malnutrition was associated with lower AUC0–24 for isoniazid and pyrazinamide. N-acetyltransferase 2 rapid acetylators had lower isoniazid AUC0–24 and slow acetylators had higher isoniazid AUC0–24 than intermediate acetylators. Determinants of Cmax were generally similar to those for AUC0–24. Conclusions This study provides the most comprehensive estimates of plasma exposures to first-line anti-TB drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualis
- Published
- 2023
- Full Text
- View/download PDF
20. THE DETERMINANTS OF SHORTER TIME TAKEN TO REACH FULL FEED AMONG EXTREMELY LOW BIRTH WEIGHT NEWBORNS ADMITTED TO LEVEL III NEONATAL INTENSIVE CARE UNIT OF GOVERNMENT HOSPITAL
- Author
-
Manesh Uddhav Kale, Isha Deshmukh, Kinikar, Aarti, Valvi, Chhaya, and Dawre, Rahul
- Subjects
ELBW NEC VS GA NICU - Abstract
Background:Although extremely low gestational age newborns (ELGANs) or extremely low birth weight (ELBW)newborns are born they have their third-trimester intrauterine life pertaining to development. During this time, one of theobjectives of the NICU staff is to feed the newborn with enough nourishment to reach a growth velocity (GV) comparable to intrauterine GV. Early parenteral & enteral nutritionto ELBW infants during the first twenty-four hrs of life leads to a quick recovery of weight loss, enhanced overall weight growth, and earlier accomplishment of complete enteral feeding. Early & substantial protein administration has also been linked to increased weight gain & brain growth. Aims/Objective:To identify determinants of shorter time taken to reach full feeds among ELBW admitted to level III NICU. Method:It was a retrospective hospital-based study conducted from April 2022 to September 2022 and included 55 ELBW newborns admitted to NICU satisfying the WHO definition of ELBW and categorizedinto group I(28 wks. till 31 wks.). Various determinants like ventilatory support, surfactant therapy, NEC, gestational age (GA), etc. are used for analysis. Results:55 ELBW analysed their mean gestational age (27±3.1) weeks, Range (25-31 weeks) Mean Birth weight (884±114 gram) Range (500- Conclusion:ELBW newborns who require minimal ventilatory support, no surfactant, less association with NEC, IVH, Sepsis, and average gestation age above 28 weeks attained early full feed regain birth weight also decreases hospital stay. Funding source:None. Ethics committee clearance submitted Conflict of interest:None.  
- Published
- 2023
- Full Text
- View/download PDF
21. COVID-19: Important Issues for Pediatricians
- Author
-
Kinikar, Aarti A. and Kulkarni, Rajesh K.
- Published
- 2020
- Full Text
- View/download PDF
22. Impact of COVID-19 on Children and Pediatricians
- Author
-
Kulkarni, Rajesh K, Kinikar, Aarti A, and Chandanwale, Ajay
- Published
- 2020
- Full Text
- View/download PDF
23. The changing characteristics of a cohort of children and adolescents living with HIV at antiretroviral therapy initiation in Asia.
- Author
-
Sornillo, Johanna Beulah, Ditangco, Rossana, Kinikar, Aarti, Wati, Dewi Kumara, Du, Quy Tuan, Nguyen, Dinh Qui, Khol, Vohith, Nguyen, Lam Van, Puthanakit, Thanyawee, Ounchanum, Pradthana, Kurniati, Nia, Chokephaibulkit, Kulkanya, Jamal Mohamed, Thahira A., Sudjaritruk, Tavitiya, Fong, Siew Moy, Kumarasamy, Nagalingeswaran, Kosalaraksa, Pope, Nallusamy, Revathy A., Nik Yusoff, Nik Khairulddin, and Sohn, Annette H.
- Subjects
HIV-positive children ,HIV-positive teenagers ,HIV ,ANTIRETROVIRAL agents ,ORPHANS ,TEENAGE girls ,DIAGNOSIS of HIV infections ,OPPORTUNISTIC infections - Abstract
Despite improvements in HIV testing and earlier antiretroviral therapy (ART) initiation in children living with HIV through the years, a considerable proportion start treatment with advanced disease. We studied characteristics of children and adolescents living with HIV and their level of immunodeficiency at ART initiation using data from a multi-country Asian cohort. We included children and adolescents who were ART-naïve and <18 years of age at ART initiation from 2011 to 2020 at 17 HIV clinics in six countries. Incidence rates of opportunistic infections (OIs) in the first two years of triple-drug ART (≥3 antiretrovirals) was also reported. Competing risk regression analysis was performed to identify factors associated with first occurrence of OI. In 2,027 children and adolescents (54% males), median age at ART initiation increased from 4.5 years in 2011–2013 to 6.7 in 2017–2020, median CD4 count doubled from 237 cells/μl to 466 cells/μl, and proportion of children who initiated ART as severely immunodeficient decreased from 70% to 45%. During follow-up, 275 (14%) children who received triple-drug ART as first treatment and had at least one clinic visit, developed at least one OI in the first two years of treatment (9.40 per 100 person-years). The incidence rate of any first OI declined from 12.52 to 7.58 per 100 person-years during 2011–2013 and 2017–2020. Lower hazard of OIs were found in those with age at first ART 2–14 years, current CD4 ≥200 cells/μl, and receiving ART between 2017 and 2020. The analysis demonstrated increasing number of children and adolescents starting ART with high CD4 count at ART start. The rate of first OI markedly decreased in children who started ART in more recent years. There remains a clear need for improvement in HIV control strategies in children, by promoting earlier diagnosis and timely treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. “Mobilizing our leaders”: A multi-country qualitative study to increase the representation of women in global health leadership
- Author
-
Riche, Claudia T., primary, Reif, Lindsey K., additional, Nguyen, Natalie T., additional, Alakiu, G. Rinu, additional, Seo, Grace, additional, Mathad, Jyoti S., additional, McNairy, Margaret L., additional, Cordeiro, Alexandra A., additional, Kinikar, Aarti, additional, Walsh, Kathleen F., additional, Deschamps, Marie Marcelle, additional, Nerette, Sandy, additional, Nimkar, Smita, additional, Kayange, Neema, additional, Jaka, Hyasinta, additional, Mwaisungu, Halima M., additional, Morona, Domenica, additional, Peter, Thandiwe Yvonne, additional, Suryavanshi, Nishi, additional, Fitzgerald, Daniel W., additional, Downs, Jennifer A., additional, and Hokororo, Adolfine, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
- Author
-
Gafar, Fajri, primary, Wasmann, Roeland E., additional, McIlleron, Helen M., additional, Aarnoutse, Rob E., additional, Schaaf, H. Simon, additional, Marais, Ben J., additional, Agarwal, Dipti, additional, Antwi, Sampson, additional, Bang, Nguyen D., additional, Bekker, Adrie, additional, Bell, David J., additional, Chabala, Chishala, additional, Choo, Louise, additional, Davies, Geraint R., additional, Day, Jeremy N., additional, Dayal, Rajeshwar, additional, Denti, Paolo, additional, Donald, Peter R., additional, Engidawork, Ephrem, additional, Garcia-Prats, Anthony J., additional, Gibb, Diana, additional, Graham, Stephen M., additional, Hesseling, Anneke C., additional, Heysell, Scott K., additional, Idris, Misgana I., additional, Kabra, Sushil K., additional, Kinikar, Aarti, additional, Kumar, Agibothu K. Hemanth, additional, Kwara, Awewura, additional, Lodha, Rakesh, additional, Magis-Escurra, Cecile, additional, Martinez, Nilza, additional, Mathew, Binu S., additional, Mave, Vidya, additional, Mduma, Estomih, additional, Mlotha-Mitole, Rachel, additional, Mpagama, Stellah G., additional, Mukherjee, Aparna, additional, Nataprawira, Heda M., additional, Peloquin, Charles A., additional, Pouplin, Thomas, additional, Ramachandran, Geetha, additional, Ranjalkar, Jaya, additional, Roy, Vandana, additional, Ruslami, Rovina, additional, Shah, Ira, additional, Singh, Yatish, additional, Sturkenboom, Marieke G.G., additional, Svensson, Elin M., additional, Swaminathan, Soumya, additional, Thatte, Urmila, additional, Thee, Stephanie, additional, Thomas, Tania A., additional, Tikiso, Tjokosela, additional, Touw, Daan J., additional, Turkova, Anna, additional, Velpandian, Thirumurthy, additional, Verhagen, Lilly M., additional, Winckler, Jana L., additional, Yang, Hongmei, additional, Yunivita, Vycke, additional, Taxis, Katja, additional, Stevens, Jasper, additional, and Alffenaar, Jan-Willem C., additional
- Published
- 2022
- Full Text
- View/download PDF
26. Protocol Driven Extubation in Neonates- A Quality Improvement Initiative
- Author
-
Kulkarni, Rajesh, Kinikar, Aarti, and Prasad, Rameshwar
- Published
- 2020
- Full Text
- View/download PDF
27. A retrospective analysis of respiratory virus transmission before and during the COVID-19 pandemic in Pune the western region of India
- Author
-
Bhardwaj, Sumit, primary, Choudhary, Manohar Lal, additional, Jadhav, Sheetal, additional, Vipat, Veena, additional, Ghuge, Rohan, additional, Salvi, Sonali, additional, Kulkarni, Rajesh, additional, Kinikar, Aarti, additional, Padbidri, Vikram, additional, Bafna, Sanjay, additional, Bavdekare, Ashish, additional, D'costa, Pradeep, additional, Gujar, Nilesh, additional, and Potdar, Varsha, additional
- Published
- 2022
- Full Text
- View/download PDF
28. Drug-resistant Enterobacteriaceae colonization is associated with healthcare utilization and antimicrobial use among inpatients in Pune, India
- Author
-
Bharadwaj, Renu, Robinson, Matthew L, Balasubramanian, Usha, Kulkarni, Vandana, Kagal, Anju, Raichur, Priyanka, Khadse, Sandhya, Kadam, Dileep, Valvi, Chhaya, Kinikar, Aarti, Kanade, Savita, Suryavanshi, Nishi, Marbaniang, Ivan, Nelson, George, Johnson, Julia, Zenilman, Jonathan, Sachs, Jonathan, Gupta, Amita, and Mave, Vidya
- Published
- 2018
- Full Text
- View/download PDF
29. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial
- Author
-
Chabala, Chishala, Turkova, Anna, Thomason, Margaret J., Wobudeya, Eric, Hissar, Syed, Mave, Vidya, van der Zalm, Marieke, Palmer, Megan, Kapasa, Monica, Bhavani, Perumal K., Balaji, Sarath, Raichur, Priyanka A., Demers, Anne-Marie, Hoddinott, Graeme, Owen-Powell, Ellen, Kinikar, Aarti, Musoke, Philippa, Mulenga, Veronica, Aarnoutse, Rob, McIlleron, Helen, Hesseling, Anneke, Crook, Angela M., Cotton, Mark, Gibb, Diana M., and on behalf of the SHINE trial team
- Published
- 2018
- Full Text
- View/download PDF
30. Clinical Profile of SARS-CoV-2-Infected Neonates
- Author
-
Kulkarni, Rajesh K, primary, Valvi, Chhaya, additional, Dawre, Rahul, additional, Rajput, Uday, additional, Nagpal, Rema, additional, Deshmukh, Isha, additional, Kamath, Pragathi, additional, Harwani, Richa, additional, Srinivasarangan, Ramya, additional, Sonteke, Somendra, additional, R, Apoorva, additional, Kamble, Savita, additional, Naik, Shilpa, additional, Bhosale, Ramesh, additional, Waghmare, Rakeesh, additional, Modi, Deepak, additional, Gajbhiye, Rahul, additional, and Kinikar, Aarti A, additional
- Published
- 2022
- Full Text
- View/download PDF
31. Utility of the interferon-gamma release assay for latent tuberculosis infection screening among indian health-care workers
- Author
-
Girish, Sunita, Kinikar, Aarti, Pardesh, Geeta, Shelke, Sangita, Basavaraj, Anita, Chandanwale, Ajay, Kadam, Dileep, Josh, Samir, Dhumal, Gauri, Lokhande, Nilima, Deluca, Andrea, Gupte, Nikhil, Gupta, Amita, Bollinger, Robert C, and Mave, Vidya
- Subjects
latent tuberculosis infection ,quanti feron® tb gold test-in-tube (qft-git) ,tuberculin skin test ,Original Article ,health-care workers ,concordant and discordant test results ,Public aspects of medicine ,RA1-1270 ,bacterial infections and mycoses - Abstract
Background: The utility of interferon-gamma release assays (IGRAs) for latent tuberculosis infection (LTBI) screening among health-care workers (HCWs) in low- and middle-income countries (LMICs) remains unclear. Methods: This was a prospective cohort study among HCW trainees undergoing annual LTBI screening via tuberculin skin test (TST) and QuantiFERON® TB Gold Test-in-tube (QFT-GIT) in Pune, India. TST induration ≥ 10 mm and QFT-GIT ≥ 0.35 IU/ml were considered positive. Test concordance was evaluated at entry among the entire cohort and at 1 year among baseline TST-negative participants with follow-up testing. Overall test agreement was evaluated at both timepoints using the kappa statistic: fair (k < 0.40), good (0.41 ≥ k ≤0.60), or strong (k > 0.60). Results: Of 200 participants, prevalent LTBI was detected in 42 (21%) via TST and 45 (23%) via QFT-GIT; QFT-GIT was positive in 27/42 (64%) TST-positive and 18/158 (11%) TST-negative trainees. Annual TST conversion was 28% (40/142) and included 11 trainees with baseline TST-/IGRA+; QFT-GIT was positive in 17/40 (43%) TST-positive and 5/102 (5%) TST-negative trainees. Overall test concordance was 84% (k = 0.52; 95% confidence interval [CI]: 0.38–0.66) and 80% (k = 0.44; 95% CI: 0.29–0.59) at baseline and 12 months, respectively. Conclusions: We observed good overall agreement between TST and QFT-GIT, and QFT-GIT detected additional LTBI cases among TST-negative trainees with possible early detection of LTBI conversion. Overall, our results support the use of IGRA for annual LTBI screening among HCWs in a high burden LMIC setting.
- Published
- 2021
32. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
- Author
-
Turkova, Anna, Wills, Genevieve H, Wobudeya, Eric, Chabala, Chishala, Palmer, Megan, Kinikar, Aarti, Hissar, Syed, Choo, Louise, Musoke, Philippa, Mulenga, Veronica, Mave, Vidya, Joseph, Bency, LeBeau, Kristen, Thomason, Margaret J, Mboizi, Robert B, Kapasa, Monica, van der Zalm, Marieke M, Raichur, Priyanka, Bhavani, Perumal K, McIlleron, Helen, Demers, Anne-Marie, Aarnoutse, Rob, Love-Koh, James, Seddon, James A, Welch, Steven B, Graham, Stephen M, Hesseling, Anneke C, Gibb, Diana M, Crook, Angela M, and SHINE Trial Team
- Abstract
BACKGROUND: Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen. METHODS: We conducted an open-label, treatment-shortening, noninferiority trial involving children with nonsevere, symptomatic, presumably drug-susceptible, smear-negative tuberculosis in Uganda, Zambia, South Africa, and India. Children younger than 16 years of age were randomly assigned to 4 months (16 weeks) or 6 months (24 weeks) of standard first-line antituberculosis treatment with pediatric fixed-dose combinations as recommended by the World Health Organization. The primary efficacy outcome was unfavorable status (composite of treatment failure [extension, change, or restart of treatment or tuberculosis recurrence], loss to follow-up during treatment, or death) by 72 weeks, with the exclusion of participants who did not complete 4 months of treatment (modified intention-to-treat population). A noninferiority margin of 6 percentage points was used. The primary safety outcome was an adverse event of grade 3 or higher during treatment and up to 30 days after treatment. RESULTS: From July 2016 through July 2018, a total of 1204 children underwent randomization (602 in each group). The median age of the participants was 3.5 years (range, 2 months to 15 years), 52% were male, 11% had human immunodeficiency virus infection, and 14% had bacteriologically confirmed tuberculosis. Retention by 72 weeks was 95%, and adherence to the assigned treatment was 94%. A total of 16 participants (3%) in the 4-month group had a primary-outcome event, as compared with 18 (3%) in the 6-month group (adjusted difference, -0.4 percentage points; 95% confidence interval, -2.2 to 1.5). The noninferiority of 4 months of treatment was consistent across the intention-to-treat, per-protocol, and key secondary analyses, including when the analysis was restricted to the 958 participants (80%) independently adjudicated to have tuberculosis at baseline. A total of 95 participants (8%) had an adverse event of grade 3 or higher, including 15 adverse drug reactions (11 hepatic events, all but 2 of which occurred within the first 8 weeks, when the treatments were the same in the two groups). CONCLUSIONS: Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis. (Funded by the U.K. Medical Research Council and others; SHINE ISRCTN number, ISRCTN63579542.).
- Published
- 2022
33. Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis
- Author
-
Aibana, Omowunmi, Huang, Chuan-Chin, Aboud, Said, Arnedo-Pena, Alberto, Becerra, Mercedes C., Bellido-Blasco, Juan Bautista, Bhosale, Ramesh, Calderon, Roger, Chiang, Silvia, Contreras, Carmen, Davaasambuu, Ganmaa, Fawzi, Wafaie W., Franke, Molly F., Galea, Jerome T., Garcia-Ferrer, Daniel, Gil-Fortuño, Maria, Gomila-Sard, Barbará, Gupta, Amita, Gupte, Nikhil, Hussain, Rabia, Iborra-Millet, Jesus, Iqbal, Najeeha T., Juan-Cerdán, Jose Vicente, Kinikar, Aarti, Lecca, Leonid, Mave, Vidya, Meseguer-Ferrer, Noemi, Montepiedra, Grace, Mugusi, Ferdinand M., Owolabi, Olumuyiwa A., Parsonnet, Julie, Roach-Poblete, Freddy, Romeu-García, Maria Angeles, Spector, Stephen A., Sudfeld, Christopher R., Tenforde, Mark W., Togun, Toyin O., Yataco, Rosa, Zhang, Zibiao, and Murray, Megan B.
- Subjects
Tuberculosis -- Care and treatment -- Risk factors -- Development and progression ,Vitamin D -- Health aspects ,Vitamin D deficiency ,HIV patients ,Infection control ,HIV ,Households ,Vitamins ,Medical research ,Health screening ,Biological sciences - Abstract
Background Few studies have evaluated the association between preexisting vitamin D deficiency and incident tuberculosis (TB). We assessed the impact of baseline vitamins D levels on TB disease risk. Methods and findings We assessed the association between baseline vitamin D and incident TB in a prospective cohort of 6,751 HIV-negative household contacts of TB patients enrolled between September 1, 2009, and August 29, 2012, in Lima, Peru. We screened for TB disease at 2, 6, and 12 months after enrollment. We defined cases as household contacts who developed TB disease at least 15 days after enrollment of the index patient. For each case, we randomly selected four controls from among contacts who did not develop TB disease, matching on gender and year of age. We also conducted a one-stage individual-participant data (IPD) meta-analysis searching PubMed and Embase to identify prospective studies of vitamin D and TB disease until June 8, 2019. We included studies that assessed vitamin D before TB diagnosis. In the primary analysis, we defined vitamin D deficiency as 25-(OH)D 75nmol/L. We estimated the association between baseline vitamin D status and incident TB using conditional logistic regression in the Lima cohort and generalized linear mixed models in the meta-analysis. We further defined severe vitamin D deficiency as 25-(OH)D < 25 nmol/L and performed stratified analyses by HIV status in the IPD meta-analysis. In the Lima cohort, we analyzed 180 cases and 709 matched controls. The adjusted odds ratio (aOR) for TB risk among participants with baseline vitamin D deficiency compared to sufficient vitamin D was 1.63 (95% CI 0.75-3.52; p = 0.22). We included seven published studies in the meta-analysis and analyzed 3,544 participants. In the pooled analysis, the aOR was 1.48 (95% CI 1.04-2.10; p = 0.03). The aOR for severe vitamin D deficiency was 2.05 (95% CI 0.87-4.87; p trend for decreasing 25-(OH)D levels from sufficient vitamin D to severe deficiency = 0.02). Among 1,576 HIV-positive patients, vitamin D deficiency conferred a 2-fold (aOR 2.18, 95% CI 1.22-3.90; p = 0.01) increased risk of TB, and the aOR for severe vitamin D deficiency compared to sufficient vitamin D was 4.28 (95% CI 0.85-21.45; p = 0.08). Our Lima cohort study is limited by the short duration of follow-up, and the IPD meta-analysis is limited by the number of possible confounding covariates available across all studies. Conclusion Our findings suggest vitamin D predicts TB disease risk in a dose-dependent manner and that the risk of TB disease is highest among HIV-positive individuals with severe vitamin D deficiency. Randomized control trials are needed to evaluate the possible role of vitamin D supplementation on reducing TB disease risk., Author(s): Omowunmi Aibana 1, Chuan-Chin Huang 2, Said Aboud 3, Alberto Arnedo-Pena 4, Mercedes C. Becerra 2, Juan Bautista Bellido-Blasco 4, Ramesh Bhosale 5, Roger Calderon 6, Silvia Chiang 7, [...]
- Published
- 2019
- Full Text
- View/download PDF
34. Clinical Profile and Outcome of Hospitalized Confirmed Cases of Omicron Variant of SARS-CoV-2 Among Children in Pune, India
- Author
-
Kinikar, Aarti A, primary, Vartak, Sagar, additional, Dawre, Rahul, additional, Valvi, Chhaya, additional, Kamath, Pragathi, additional, Sonkawade, Naresh, additional, Pawar, Sameer, additional, Bhagat, Vaishnavi, additional, A, Kiruthiga, additional, Nawale, Komal, additional, Deshmukh, Isha, additional, Das, Rashmita, additional, Kulkarni, Rajesh K, additional, Potdar, Varsha, additional, and Karyakarte, Rajesh, additional
- Published
- 2022
- Full Text
- View/download PDF
35. Additional file 1 of Development of shortened HIV-related stigma scales for young people living with HIV and young people affected by HIV in India
- Author
-
Marbaniang, Ivan, Borse, Rohidas, Sangle, Shashikala, Kinikar, Aarti, Chavan, Amol, Nimkar, Smita, Suryavanshi, Nishi, and Mave, Vidya
- Abstract
Additional file 1. Supplementary Table 1: Original Berger scale items (HSS) and factors that load on subscales. Supplementary Table 2: Factor loadings for the scales described by Rongkavilit et al. and Reinius et al. for YPLHIV. Supplementary Table 3: Confirmatory factor analysis model fit indices for a combination of stigma scales from different authors for YPLHIV. Supplementary Figure 1: Path diagram for PHSS. Supplementary Figure 2: Path diagram for modified-PHSS.
- Published
- 2022
- Full Text
- View/download PDF
36. The Kynurenine/Tryptophan Ratio Is a Sensitive Biomarker for the Diagnosis of Pediatric Tuberculosis Among Indian Children
- Author
-
Tornheim, Jeffrey A., primary, Paradkar, Mandar, additional, Zhao, Henry, additional, Kulkarni, Vandana, additional, Pradhan, Neeta, additional, Kinikar, Aarti, additional, Kagal, Anju, additional, Gupte, Nikhil, additional, Mave, Vidya, additional, Gupta, Amita, additional, and Karakousis, Petros C., additional
- Published
- 2022
- Full Text
- View/download PDF
37. Implementation of the Comprehensive Unit-Based Safety Program to Improve Infection Prevention and Control Practices in Four Neonatal Intensive Care Units in Pune, India
- Author
-
Johnson, Julia, primary, Latif, Asad, additional, Randive, Bharat, additional, Kadam, Abhay, additional, Rajput, Uday, additional, Kinikar, Aarti, additional, Malshe, Nandini, additional, Lalwani, Sanjay, additional, Parikh, Tushar B., additional, Vaidya, Umesh, additional, Malwade, Sudhir, additional, Agarkhedkar, Sharad, additional, Curless, Melanie S., additional, Coffin, Susan E., additional, Smith, Rachel M., additional, Westercamp, Matthew, additional, Colantuoni, Elizabeth, additional, Robinson, Matthew L., additional, Mave, Vidya, additional, Gupta, Amita, additional, Manabe, Yukari C., additional, and Milstone, Aaron M., additional
- Published
- 2022
- Full Text
- View/download PDF
38. Association of Maternal Inflammation During Pregnancy With Birth Outcomes and Infant Growth Among Women With or Without HIV in India
- Author
-
Shafiq, Mehr, primary, Mathad, Jyoti S., additional, Naik, Shilpa, additional, Alexander, Mallika, additional, Yadana, Su, additional, Araújo-Pereira, Mariana, additional, Kulkarni, Vandana, additional, Deshpande, Prasad, additional, Kumar, Nathella Pavan, additional, Babu, Subash, additional, Andrade, Bruno B., additional, Leu, Cheng-Shiun, additional, Khwaja, Saltanat, additional, Bhosale, Ramesh, additional, Kinikar, Aarti, additional, Gupta, Amita, additional, and Shivakoti, Rupak, additional
- Published
- 2021
- Full Text
- View/download PDF
39. Breastfeeding in Coronavirus Disease 2019 (COVID-19): Position Statement of Indian Academy of Pediatrics and Infant and Young Child Feeding Chapter
- Author
-
Bharadva, Ketan, primary, Bellad, Roopa M., additional, Tiwari, Satish, additional, Somasekar, R., additional, Phadke, Mrudula, additional, Bodhankar, Uday, additional, Bang, Akash, additional, Kinikar, Aarti Avinash, additional, Mallikarjuna, H. B., additional, Shah, Jayant, additional, Khurana, Omesh, additional, Gunasingh, D., additional, Basavaraja, G. V., additional, Kumar, Remesh, additional, and Gupta, Piyush, additional
- Published
- 2021
- Full Text
- View/download PDF
40. Screening of Extended Family Members of Thalassemia Major Children as a Thalassemia Preventive Strategy.
- Author
-
Sonkawade, Naresh Dattatraya, Kinikar, Aarti Avinash, Kulkarni, Rajesh K., Dawre, Rahul M., Valvi, Chhaya T., and Kamath, Pragathi A.
- Subjects
- *
BETA-Thalassemia , *EXTENDED families , *MEDICAL screening , *HIGH performance liquid chromatography , *BLOOD cell count - Abstract
BACKGROUND: Thalassemia is considered as the most common single gene disorder worldwide. Preventive measures include identification of thalassemia carriers (traits) through screening, genetic counselling and prenatal diagnosis to reduce the incidence. This study aims at estimating the prevalence of carrier status detection among the extended family members of children having thalassemia major so as to use it as a screening prevention strategy with appropriate counselling. METHODS: This cross-sectional study was conducted in thalassemia unit of Pediatric Department of a tertiary care teaching hospital over a period of 18 months. Blood samples were collected from 117 extended family members (EFM) of 23 children with thalassemia major to carry out investigations such as Complete Blood Counts (CBC), Naked Eye Single Tube Red Cell Osmotic Fragility Test (NESTROFT), Reticulocyte count, High Performance Liquid Chromatography(HPLC) and serum ferritin. Reports were analysed to find out the prevalence of carriers. RESULTS: Among 117 EFM, 62 (52.9%) were males while 55(47.1%) were females. Mean age distribution in this study was 16.49 years (8.5). Prevalence of thalassemia trait (carrier) was 35%. NESTROFT test was positive in 57(48.7%) participants. The binary logistic regression found only positive NESTROFT test as a predictor (adjusted OR=0.022, P=0.001) of having raised HbA2 (HbA2≥3.5 %). CONCLUSION: Screening of thalassemia carrier by targeting extended family members of thalassemia major children could yield more carrier cases and targeted counselling could help effectively in decreasing the number of children born with thalassemia major. This strategy could be included in future plan of national prevention programme for thalassemia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Delayed Development of Dilated Cardiomyopathy in an Adolescent Following Electrocution
- Author
-
Kulkarni, Rajesh, Vartak, Sagar, Sonkawade, Naresh, Kinikar, Aarti, Kulkarni, Rajesh, Vartak, Sagar, Sonkawade, Naresh, and Kinikar, Aarti
- Abstract
Electrical injuries frequently affect the cardiovascular system. Most of the patients have immediate devastating effects. Permanent myocardial injury or chronic cardiac disease following an electrocution is rare. We report a 10-year-old female with a history of electrocution who presented to us with dilated cardiomyopathy with severe left ventricular dysfunction.
- Published
- 2021
42. Accidental Poisoning by Dieffenbachia (Dumb cane) Plant- a must know for Emergency Physician
- Author
-
Kulkarni, Rajesh, Kinikar, Aarti, Modi, Tanvi, Kanu, Takam, Aathira, K C, Kaur, Arvinder, Ahir, Priitee, Kulkarni, Rajesh, Kinikar, Aarti, Modi, Tanvi, Kanu, Takam, Aathira, K C, Kaur, Arvinder, and Ahir, Priitee
- Published
- 2020
43. A rare case of factor XIII deficiency presenting with scrotal hematoma in an adolescent
- Author
-
Kulkarni, RajeshK, primary, Vartak, Sagar, additional, Karandikar, Niharika, additional, and Kinikar, Aarti, additional
- Published
- 2021
- Full Text
- View/download PDF
44. 1378. Reservoirs of Transmission of Resistant Gram-negative Pathogens Responsible for Neonatal Sepsis among Hospitalized Neonates in Pune, India
- Author
-
Johnson, Julia, primary, Johnson, Julia, additional, Robinson, Matthew, additional, Naik, Shilpa Nandkumar, additional, Patil, Sunil, additional, Kulkarni, Rajesh, additional, Kinikar, Aarti, additional, Dohe, Vaishali, additional, Mudshinkar, Swati, additional, Smith, Rachel, additional, Westercamp, Matthew, additional, Randive, Bharat, additional, Kadam, Abhay, additional, Kulkarni, Vandana, additional, Mave, Vidya, additional, Gupta, Amita, additional, Milstone, Aaron, additional, and Manabe, Yukari C, additional
- Published
- 2020
- Full Text
- View/download PDF
45. Ethics and the COVID-19 pandemic; A clinician’s perspective
- Author
-
Kulkarni, Rajesh K, primary and Kinikar, Aarti A, primary
- Published
- 2020
- Full Text
- View/download PDF
46. Impact of the Fogarty Training Program on Trainee and Institutional Research Capacity Building at a Government Medical College in India
- Author
-
Dhumal, Gauri, primary, DeLuca, Andrea, additional, Chandanwale, Ajay, additional, Kadam, Dileep, additional, Joshi, Samir, additional, Kinikar, Aarti, additional, Gupte, Nikhil, additional, Mave, Vidya, additional, Gupta, Amita, additional, Suryavanshi, Nishi, additional, and Bollinger, Robert C., additional
- Published
- 2020
- Full Text
- View/download PDF
47. Acute Encephalopathy in a Child with Coronavirus Disease-2019 Infection
- Author
-
Kinikar, Aarti, primary, Kulkarni, Rajesh, additional, Rajput, Uday, additional, and Karyakarte, Rajesh, additional
- Published
- 2020
- Full Text
- View/download PDF
48. Hyaline Fibromatosis Syndrome: Report and Literature review of a Rare and Fatal Genetic Disorder
- Author
-
Kulkarni, Rajesh K, Kinikar, Aarti A, Prasad, Brijender, Nair, Greeshma, Vartak, Sagar, Kulkarni, Rajesh K, Kinikar, Aarti A, Prasad, Brijender, Nair, Greeshma, and Vartak, Sagar
- Abstract
Hyaline fibromatosis syndrome is a very rare condition caused by mutations in the ANTXR2 gene and characterized by nodular skin lesions, joint contractures and visceral involvement in the severe variant. Most children who have the severe variant (Infantile systemic hyalinosis-ISH) succumb by 2 years of age while those with milder form (Juvenile Hyaline Fibromatosis-JHF) without visceral involvement may live till second decade. We present an 8 years old boy with overlap features of ISH and JHF and a dysplastic kidney. Association of dysplastic kidney with HFS has not been reported before to the best of our knowledge.
- Published
- 2019
49. Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India
- Author
-
Ram Malathi, Gupte Nikhil, Nayak Uma, Kinikar Aarti A, Khandave Mangesh, Shankar Anita V, Sastry Jayagowri, Bollinger Robert C, and Gupta Amita
- Subjects
HIV-exposed infants ,Growth patterns ,India ,Extended use of nevirapine ,Risk factors ,Timing of HIV Infection ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background India has among the highest rates of infant malnutrition. Few studies investigating the growth patterns of HIV-exposed infants in India or the impact of timing of HIV infection on growth in settings such as India exist. Methods We used data from the Six Week Extended Nevirapine (SWEN) trial to compare the growth patterns of HIV-infected and HIV-exposed but uninfected infants accounting for timing of HIV infection, and to identify risk factors for stunting, underweight and wasting. Growth and timing of HIV infection were assessed at weeks 1, 2, 4, 6, 10, 14 weeks and 6, 9, 12 months of life. Random effects multivariable logistic regression method was used to assess factors associated with stunting, underweight and wasting. Results Among 737 HIV-exposed infants, 93 (13%) were HIV-infected by 12 months of age. Among HIV-infected and uninfected infants, baseline prevalence of stunting (48% vs. 46%), underweight (27% vs. 26%) and wasting (7% vs. 11%) was similar (p>0.29), but by 12 months stunting and underweight, but not wasting, were significantly higher in HIV-infected infants (80% vs. 56%, 52% vs. 29%, p< 0.0001; 5% vs. 6%, p=0.65, respectively). These differences rapidly manifested within 4–6 weeks of birth. Infants infected in utero had the worst growth outcomes during the follow-up period. SWEN was associated with non-significant reductions in stunting and underweight among HIV-infected infants and significantly less wasting in HIV-uninfected infants. In multivariate analysis, maternal CD4 < 250, infant HIV status, less breastfeeding, low birth weight, non-vaginal delivery, and infant gestational age were significant risk factors for underweight and stunting. Conclusion Baseline stunting and underweight was high in both HIV-infected and uninfected infants; growth indices diverged early and were impacted by timing of infection and SWEN prophylaxis. Early growth monitoring of all HIV-exposed infants is an important low-cost strategy for improving health and survival outcomes of these infants. Trial Registration NCT00061321
- Published
- 2012
- Full Text
- View/download PDF
50. Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study
- Author
-
Hompe, Eliza D., primary, Jacobson, Denise L., additional, Eudailey, Joshua A., additional, Butler, Kevin, additional, Edwards, Whitney, additional, Pollara, Justin, additional, Brummel, Sean S., additional, Fouda, Genevieve G., additional, Chinula, Lameck, additional, Kamanga, Melvin, additional, Kinikar, Aarti, additional, Moodley, Dhayendre, additional, Owor, Maxensia, additional, Fowler, Mary Glenn, additional, and Permar, Sallie R., additional
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.